For the quarter ending 2025-09-30, TVGN had $351,865 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Purchases of property and equipment | - | 0 |
| Net cash used in investing activities | 0 | 0 |
| Non-cash interest expense | 0 | 0 |
| Merger transaction costs | 0 | 0 |
| Change in fair value of convertible promissory notes | 0 | 0 |
| Loss on series a preferred stock issuance | 0 | 0 |
| Loss on issuance of commitment shares | 0 | 0 |
| Issuance of written call option | 0 | 0 |
| Change in fair value of written call option derivative liabilities | 0 | 0 |
| Depreciation expense | 518 | 131,994 |
| Stock-based compensation expense | 3,244,917 | 10,532,034 |
| Change in fair value of warrants | -64,959 | 7,553 |
| Amortization of right-of-use asset | 26,707 | 264,192 |
| Prepaid expenses and other assets | -308,302 | 297,763 |
| Other assets | 0 | -9,957 |
| Accounts payable | -1,032,371 | -959,943 |
| Accrued expenses and other liabilities | -379,140 | -71,206 |
| Operating lease liabilities | -26,706 | -243,544 |
| Net loss | -5,726,812 | -15,871,040 |
| Net cash used in operating activities | -3,649,544 | -6,497,766 |
| Cash acquired in connection with the reverse recapitalization | 0 | 0 |
| Proceeds from issuance of series a preferred stock | 0 | 0 |
| Proceeds from loan agreement | - | 3,400,000 |
| Proceeds from issuance of series c preferred stock | 0 | - |
| Nonrefundable prepaid proceeds towards anticipated series a-1 preferred stock issuance | 0 | 0 |
| Capital contributions | 1,000,000 | 2,500,000 |
| Payment of offering costs associated with the sales agreement | 100,000 | - |
| Proceeds from issuance of shares under the sales agreement, net of offering costs | 3,101,409 | - |
| Proceeds from loan agreement | 3,400,000 | - |
| Net cash provided by financing activities | 4,001,409 | 5,900,000 |
| Net (decrease) increase in cash | 351,865 | -597,766 |
| Cash and cash equivalents at beginning of period | 1,282,995 | - |
| Cash and cash equivalents at end of period | 1,037,094 | - |
Tevogen Bio Holdings Inc. (TVGN)
Tevogen Bio Holdings Inc. (TVGN)